SL 880338

Drug Profile

SL 880338

Alternative Names: SL880338-08

Latest Information Update: 07 Jan 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi-Synthelabo
  • Class Antidepressants; Antiemetics; Antihypertensives; Antimigraines; Anxiolytics; Sleep disorder therapies
  • Mechanism of Action Serotonin 1A receptor inverse agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder; Sleep disorders

Most Recent Events

  • 07 Jan 1997 Discontinued-Preclinical for Depression in France (Unknown route)
  • 07 Jan 1997 Discontinued-Preclinical for Sleep disorders in France (Unknown route)
  • 14 Feb 1995 Discontinued-Preclinical for Anxiety disorders in France (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top